Oscar Health
OSCR
$23.73
+7.86%
Oscar Health, Inc. is a technology-driven healthcare company that offers individual, family, and small group insurance plans primarily through the Affordable Care Act (ACA) marketplaces, alongside a suite of health technology solutions. The company positions itself as a disruptive, member-centric player in the managed care industry, leveraging its proprietary full-stack technology platform to simplify healthcare navigation and improve clinical outcomes. The current investor narrative is sharply divided between the company's significant top-line growth and its ongoing path to consistent profitability, with recent news highlighting a potential value opportunity as its stock price has been volatile despite rapid member expansion and a favorable regulatory backdrop for the managed care sector.…
OSCR
Oscar Health
$23.73
Related headlines
Investment Opinion: Should I buy OSCR Today?
Rating & Thesis: Hold. OSCR presents a high-risk, high-potential-reward speculative opportunity, but the lack of consistent profitability and high volatility warrant caution until the path to sustained earnings is clearer. The recent shift in analyst sentiment to neutral aligns with this wait-and-see stance.
Supporting Evidence: The primary valuation metric, the Price-to-Sales ratio of 0.32, is at a deep discount to the industry, suggesting significant upside if profitability emerges. Revenue growth remains solid at 17.25% YoY, and the generation of $1.06 billion in TTM free cash flow provides a crucial financial cushion. However, these positives are counterbalanced by severe profitability issues, with a trailing net margin of -3.8% and a gross margin that contracted sharply to 6.6% in the last quarter, indicating the core business economics are not yet sound.
Risks & Conditions: The two biggest risks are the failure to achieve consistent positive net income and the high stock volatility (beta 1.93) that could lead to large drawdowns. This Hold rating would upgrade to a Buy if the company demonstrates two consecutive quarters of expanding gross margin above 15% and positive net income, signaling a sustainable turnaround. It would downgrade to a Sell if revenue growth decelerates below 10% or quarterly losses widen significantly beyond the Q4 2025 level of -$352.6 million. Based on current data, the stock is fairly valued relative to its own risky profile but deeply undervalued relative to sector peers—a dichotomy that will only resolve with proof of profitability.
Sign up to view all
OSCR 12-Month Price Forecast
OSCR is a binary, high-volatility bet on a pre-profitability healthcare disruptor. The neutral stance reflects the compelling risk/reward setup—extreme undervaluation versus peers against unproven earnings power—where the outcome is highly dependent on execution over the next few quarters. The stance would upgrade to bullish on concrete evidence of sustained margin expansion and profitability, likely after two clean quarters. It would turn bearish if the next earnings report shows further gross margin deterioration or a significant growth slowdown, confirming the bear thesis of a broken business model.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Oscar Health's 12-month outlook, with a consensus price target around $30.85 and implied upside of +30.0% versus the current price.
Average Target
$30.85
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$19 - $31
Analyst target range
Analyst coverage is limited, with only 4 analysts providing estimates, indicating this is a stock with lower institutional following and potentially higher volatility due to less efficient price discovery. The consensus sentiment appears mixed but has recently improved, as evidenced by upgrades from UBS (Sell to Neutral) and Barclays (Underweight to Equal Weight) in early January 2026. The average revenue estimate for the company is $21.56 billion, but specific price targets and a consensus recommendation are not available in the provided data, making it impossible to calculate a precise implied upside or downside. The recent pattern of institutional ratings shows a shift from uniformly bearish calls in late 2025 to more neutral stances in early 2026, suggesting analysts are cautiously reassessing the downside risk following the stock's severe decline and potential regulatory tailwinds.
Bulls vs Bears: OSCR Investment Factors
The investment debate for Oscar Health is a classic battle between deep-value opportunity and fundamental execution risk. The bull case, currently supported by stronger evidence due to the extreme valuation discount and powerful technical rebound, hinges on the market's extreme pessimism being overdone relative to the company's growth and cash flow. The bear case is grounded in the harsh reality of persistent, volatile losses and decelerating growth. The single most important tension is whether OSCR can translate its robust revenue growth and strong free cash flow into consistent, sustainable profitability. The resolution of this tension—specifically, the stabilization and expansion of its gross margin from the volatile, thin 6.6% level—will ultimately determine if the stock re-rates towards industry multiples or remains a speculative, loss-making story.
Bullish
- Extreme Valuation Discount: OSCR trades at a trailing PS ratio of 0.32 and EV/Sales of 0.17, representing a steep discount to the healthcare plan industry (often >1.0 PS) and near the absolute bottom of its own historical range. This deep-value pricing reflects extreme market pessimism, creating significant upside potential if the company demonstrates a credible path to profitability.
- Strong Revenue Growth Trajectory: The company maintains robust top-line expansion, with Q4 2025 revenue of $2.81 billion representing 17.25% year-over-year growth. This growth is supported by rapid member expansion and a favorable regulatory backdrop for the ACA marketplace, providing a solid foundation for future scale.
- Substantial Free Cash Flow Generation: Despite net losses, OSCR generated $1.06 billion in trailing-twelve-month free cash flow, providing ample liquidity to fund operations and growth initiatives without immediate financial distress. This strong cash generation mitigates near-term solvency risk.
- Analyst Sentiment Turning Less Bearish: Recent analyst upgrades from UBS (Sell to Neutral) and Barclays (Underweight to Equal Weight) in early 2026 signal a cautious reassessment of downside risk following the stock's severe decline. This shift in institutional sentiment suggests the floor may be forming.
Bearish
- Severe and Volatile Profitability Issues: OSCR posted a net loss of $352.6 million in Q4 2025, with gross margin collapsing to 6.6% from 25.8% in Q1 2025, highlighting extreme quarterly volatility and challenging insurance economics. Deeply negative ROE (-45.33%) and ROA (-4.44%) reflect inefficient capital use as it scales.
- Revenue Growth Deceleration: While still positive at 17.25% YoY, Q4 2025 revenue growth marks a significant slowdown from the $3.05 billion reported in Q1 2025. This deceleration raises questions about the sustainability of its growth narrative and ability to achieve operating leverage.
- Extreme Stock Volatility: With a beta of 1.932, OSCR is roughly 93% more volatile than the broader market, making it a high-risk holding unsuitable for conservative portfolios. This volatility is evidenced by a 52-week range from $10.69 to $23.80 and a max drawdown of -51.71%.
- Limited Analyst Coverage and Visibility: Only 4 analysts provide estimates, indicating lower institutional following and potentially less efficient price discovery. The lack of a consensus price target or recommendation adds uncertainty for investors seeking fundamental anchors.
OSCR Technical Analysis
The stock is in a pronounced recovery phase from deeply oversold levels, having rallied 57.63% over the past month, yet it remains in a longer-term downtrend with a 1-year price change of +41.69% that masks significant volatility. Currently trading at $18.49, the price sits approximately 59% of its 52-week range ($10.69 to $23.80), indicating it has recovered meaningfully from its lows but remains well off its highs, suggesting there is room for further recovery if the bullish momentum continues. Recent short-term momentum is exceptionally strong and diverges sharply from the longer-term trend, with the 1-month surge of 57.63% vastly outpacing the more modest 3-month gain of 28.85%, signaling a potential trend reversal or a powerful oversold bounce driven by a shift in sentiment. The stock exhibits extreme volatility with a beta of 1.932, meaning it is roughly 93% more volatile than the broader market, which is critical for risk assessment. Key technical support is at the recent 52-week low of $10.69, while resistance lies near the 52-week high of $23.80; a sustained breakout above the $19-$20 level could signal a test of higher resistance, while a failure here might see a retest of support.
Beta
2.34
2.34x market volatility
Max Drawdown
-51.7%
Largest decline past year
52-Week Range
$11-$24
Price range past year
Annual Return
+41.1%
Cumulative gain past year
| Period | OSCR Return | S&P 500 |
|---|---|---|
| 1m | +64.2% | +8.6% |
| 3m | +74.5% | +6.7% |
| 6m | +70.1% | +9.8% |
| 1y | +41.1% | +26.6% |
| ytd | +58.5% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
OSCR Fundamental Analysis
Revenue growth remains robust but is showing signs of deceleration; the most recent quarterly revenue was $2.81 billion, representing a year-over-year growth of 17.25%, yet this marks a slowdown from the stronger growth rates seen in prior quarters of 2025 (e.g., Q1 2025 revenue was $3.05 billion). The company is not consistently profitable, posting a net loss of $352.6 million in Q4 2025, though this followed a profitable Q1 2025 with net income of $275.3 million, indicating significant quarterly volatility in earnings primarily driven by medical cost seasonality. Gross margin was a thin 6.6% in Q4 2025, a sharp contraction from the 25.8% gross margin in Q1 2025, highlighting the challenging economics and cost pressures in the insurance business. The balance sheet shows a moderate debt level with a debt-to-equity ratio of 0.44, and the company generated substantial positive free cash flow of $1.06 billion on a trailing-twelve-month basis, providing liquidity to fund operations. However, return metrics are deeply negative, with an ROE of -45.33% and an ROA of -4.44%, reflecting the company's ongoing losses and inefficient use of capital as it scales.
Quarterly Revenue
$2.8B
2025-12
Revenue YoY Growth
+0.17%
YoY Comparison
Gross Margin
+0.06%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is OSCR Overvalued?
Given the company's negative net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio. Oscar Health trades at a trailing PS ratio of 0.32 and an Enterprise Value-to-Sales (EV/Sales) of 0.17, which are extremely low multiples that suggest the market is assigning little value to its revenue stream, likely due to persistent losses and margin concerns. Compared to typical healthcare plan providers, which often trade at PS ratios above 1.0, Oscar's valuation represents a steep discount to the industry, though this is arguably justified by its inferior profitability and unproven long-term earnings model. Historically, the stock's own PS ratio has fluctuated wildly, from a high above 13 in early 2021 to the current level of 0.32; trading near the absolute bottom of its historical range indicates the market is pricing in extreme pessimism, which could represent a deep-value opportunity if the company's path to profitability materializes.
PE
-8.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -28x~17x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-3.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on OSCR's unproven path to profitability amidst significant cost pressures. The company's net margin was -3.8% with a gross margin of just 14.4% on a trailing basis, but Q4 2025 revealed severe volatility with gross margin collapsing to 6.6%. This highlights the operational risk in its insurance model, where medical cost seasonality can devastate quarterly results. While the debt-to-equity ratio of 0.44 is moderate, the deeply negative ROE of -45.33% indicates capital is being destroyed as the company scales, creating dependence on continued growth to justify any valuation.
Market & Competitive Risks are pronounced due to OSCR's valuation standing and sector dynamics. Although trading at a steep discount (PS of 0.32), this discount is justified by its lack of profits compared to established, profitable peers. The stock's extreme beta of 1.932 makes it highly sensitive to market rotations away from speculative growth or risk assets. Furthermore, as a disruptor in the managed care sector, it faces intense competition from entrenched giants like UnitedHealth and CVS, which benefit from scale, diversification, and stronger balance sheets, potentially limiting OSCR's market share gains and pricing power.
Worst-Case Scenario involves a perfect storm of operational missteps and external pressure. This would entail a further deceleration of revenue growth below 10%, combined with another quarter of gross margin compression into negative territory, triggering a crisis of confidence in its business model. Coupled with an adverse regulatory shift for the ACA marketplace, this could lead to sustained net losses eroding its cash balance. In this scenario, the stock could realistically retest and break below its 52-week low of $10.69, representing a downside of approximately -42% from the current price of $18.49, potentially exacerbated by its high short interest (short ratio of 3.89).
FAQ
The key risks are, in order of severity: 1) Profitability Risk: The company is not consistently profitable, with a net loss of $352.6M in Q4 2025 and volatile gross margins, threatening its long-term viability. 2) Volatility Risk: With a beta of 1.93, the stock is roughly 93% more volatile than the market, leading to potentially large and sudden drawdowns. 3) Execution/Rate of Growth Risk: Revenue growth, while at 17.25% YoY, is decelerating, and failure to maintain strong growth could collapse the investment thesis. 4) Regulatory Risk: As an ACA marketplace-focused insurer, its business is sensitive to changes in healthcare policy and government subsidies.
The 12-month forecast is highly bifurcated, with three primary scenarios. The Base Case (50% probability) sees the stock trading between $16 and $22 as it grapples with mixed quarterly results. The Bull Case (30% probability) targets $22 to $28 on successful profitability proof and valuation re-rating. The Bear Case (20% probability) warns of a drop to $10-$15 if operational execution fails. The Base Case is most likely, predicated on the assumption that OSCR will continue its pattern of solid growth but erratic profitability, keeping investors in a holding pattern. The key variable is the trend in gross margins over the next two quarters.
OSCR is deeply undervalued based on sales multiples relative to the healthcare plan industry, which often trades above a 1.0 Price-to-Sales ratio. Its trailing PS of 0.32 and EV/Sales of 0.17 suggest the market is assigning little value to its revenue stream. However, this discount is arguably justified by its lack of consistent profitability and negative return metrics (ROE -45.33%). The valuation implies the market expects continued struggles and does not yet believe in the company's ability to convert top-line growth into bottom-line earnings. It is a classic value trap unless profitability materializes.
OSCR is a speculative buy only for investors with a high risk tolerance and a long-term horizon. The stock offers significant potential upside from its deeply discounted valuation (PS ratio of 0.32), but this is counterbalanced by severe risks, including persistent losses, extreme volatility (beta 1.93), and dependence on achieving profitability. For a risk-tolerant investor seeking a high-conviction turnaround story in healthcare, it could represent a good buy. However, for most investors, it is more appropriate to hold and wait for clearer evidence of sustained profitability before committing capital.
OSCR is unsuitable for short-term trading for all but the most sophisticated traders due to its extreme volatility (beta 1.93) and the lack of a clear near-term catalyst for a sustained move. For investors, it is a long-term, speculative holding with a minimum horizon of 2-3 years, as that is the timeframe likely required to prove or disprove its profitability thesis. The company pays no dividend and earnings visibility is low, eliminating it as an income or short-term growth play. It is purely a capital appreciation bet on a business model turnaround, which necessitates patience.